respectively.2 We now know that breast cancer encompasses a range of behaviors, from aggressive to indolent; the latter are more likely to surface with screening.3 The analysis of Narod et al4 fuels a growing concern that we should rethink our strategy for the detection and treatment of DCIS....
The resulting guidelines provide a framework for clinical decision-making for patients with DCIS based on review of relevant literature, and includes information on patient selection and evaluation, technical aspects of surgical treatment, techniques of irradiation, and follow-up care.CA: A Cancer ...
Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. Journal of Clinical Oncology : JCO2100831, 12 May 2021. Available from: URL: http://doi.org/10.1200/JCO.21.00831 Download references Rights and permissions Reprints and permissions About this article Cite this article Radiotherapy...
DCIS: Ductal carcinoma in situ LIQ: Lower inner quadrant MDT: Multi-disciplinary team MICAP: Medial intercostal artery perforator O-BCS: Oncoplastic breast-conserving surgery PROM: Patient reported outcome measures S-BCS: Standard breast conserving surgery SPSS: Statistical package for social...
said during the presentation. “Because of the benefit for the patients and the shortening of the treatment, the benefit in terms of decreased burden and the benefits for healthcare in general, I think we should now privilege the 3 weeks regimen, even for nodal radiotherap...
“Naratuximab plus Rituxan can certainly represent a new treatment option for relapsed/refractory non-Hodgkin lymphoma, especially relapsed/refractory DLBCL, which is still a particularly important unmet need for folks not candidates for potentially curative therapy ...
Pinotti, J. A. and F. M. Carvalho (2002). “Intraoperative pathological monitorization of surgical margins: a method to reduce recurrences after conservative treatment for breast cancer.” Eur J Gynaecol Oncol 23(1): 11–6. PubMedGoogle Scholar ...
Lapatinib is a dual tyrosine kinase inhibitor of HER1 and HER2, currently approved for the treatment of patients with HER2-positive advanced breast cancer who fail to respond to trastuzumab therapy (Spector et al, 2005; Geyer et al, 2006; Konecny et al, 2006; Cameron et al, 2008; Di Leo...
Neoadjuvant chemotherapy (NAC) has been the preferred treatment for locally advanced and inflammatory breast cancer patients. A multimodality approach, including NAC, surgery, and radiation, is the most effective treatment option as shown by better overall survival outcomes (Kaufmann et al, 2007). NAC...
One hormonal treatment for metastatic disease, as well as adjuvant or neoadjuvant chemotherapy with or without trastuzumab were allowed. The primary endpoint was progression-free survival (PFS). Secondary endpoints included OS, overall response rate (ORR), and duration of response. At ...